Breast cancer care begins with a thorough diagnostic process, which guides doctors in choosing the most effective treatment plan. Below we outline the key tests and procedures used to diagnose breast cancer, and explain how these findings connect to standard treatment options. We use simple language to ensure clarity, with references provided for accuracy.

Diagnostic Tests and Procedures

To determine if a suspicious breast change is cancer, doctors typically follow several steps:

1. Clinical Breast Exam (CBE): This is a physical examination of the breasts and underarm areas by a healthcare professional. The doctor carefully checks for any lumps, hard thickening, or changes in the breast tissue or nipples. A CBE is often the first step if you or your doctor notice a breast change.
2. Imaging Tests: If something abnormal is suspected, imaging tests help visualize the inside of the breast:
3. Biopsy (Confirming the Diagnosis): A biopsy is the only definite way to diagnose breast cancer. In a biopsy, the doctor removes a small sample of breast tissue or cells, which is then examined under a microscope by a pathologist. Often a core needle biopsy is performed, meaning a hollow needle is used to take tiny tissue cores from the suspicious area. Imaging guidance (using ultrasound or mammography) is usually employed to help precisely locate the area of concern for the biopsy. This procedure may be done with local anesthesia and is typically outpatient. The tissue sample is sent to a laboratory, and the resulting pathology report will confirm whether cancer is present and provide crucial details if it is:
   – Type of Cancer: The report identifies the type of breast cancer, such as ductal carcinoma (originating in milk ducts) or lobular carcinoma (originating in milk-producing lobules). It also shows whether the cancer is non-invasive (confined to the ducts/lobules, also called in situ) or invasive (has spread into surrounding breast tissue).
   – Grade: The grade describes how abnormal the cancer cells look under the microscope and how quickly they are likely to grow. A low-grade (well-differentiated) tumor has cells that look more like normal cells and tend to grow slowly, whereas a high-grade (poorly differentiated) tumor has very abnormal-looking cells that generally grow faster. Grade helps predict the cancer’s aggressiveness.
   – Receptor Status and Other Markers: Breast cancer cells are tested for certain proteins that drive growth. The key ones are hormone receptors — estrogen receptor (ER) and progesterone receptor (PR) — and the HER2 protein. If a cancer has ER or PR receptors, it is considered hormone receptor-positive (meaning it may respond to hormonal therapies). If it produces excess HER2 protein (HER2-positive), it may respond to drugs that target HER2. The pathologist’s report will indicate ER, PR, and HER2 status, which are critical for planning treatment. The report may also include a measure of how fast the cancer cells are dividing, such as the Ki-67 index – a higher Ki-67 percentage means a faster-growing tumor. All of this information from the biopsy guides the next steps in care.
4. Staging Tests (if needed): Once breast cancer is confirmed, doctors assess the stage of the disease – essentially, how far it has spread. Early-stage cancers (confined to the breast and maybe a few lymph nodes) might not need extensive scanning. But for larger tumors or if there are symptoms, additional tests will be done to see if cancer is present in other parts of the body. These may include imaging such as a chest X-ray (to check the lungs), a bone scan (to see if cancer has spread to the bones), or CT and/or PET scans of the chest and abdomen (to look at organs like the liver and lungs for any metastasis). Blood tests are also commonly done; for example, liver function tests might detect liver enzyme elevations that could suggest spread to the liver and levels of alkaline phosphatase in the blood can rise if cancer has spread to bones. These staging tests help doctors determine the stage 0 to IV classification of the cancer, which is crucial for choosing the appropriate treatment approach.

Standard Treatment Options

The treatment of breast cancer is highly personalized, but it generally follows patterns based on the cancer’s stage at diagnosis and specific tumor characteristics. The information gathered from the diagnostic steps – such as tumor size, lymph node involvement, and receptor status – directly influences the treatment plan. Below is an overview of standard treatment options by stage:

Early-Stage Breast Cancer (Stages 0–II)

Early-stage breast cancers include stage 0 (ductal carcinoma in situ, a non-invasive cancer) and stages I and II (invasive cancers that are relatively small and/or have limited spread to nearby lymph nodes). These cancers are usually treated with a focus on removing the tumor and preventing local recurrence, often with curative intent. Surgery is typically the first step for invasive early breast cancers. This may be a breast-conserving surgery (BCS, often called lumpectomy) to remove the tumor with a margin of healthy tissue, or a mastectomy to remove the entire breast, depending on the tumor’s size, location, and patient preference. In either case, surgeons will also evaluate nearby lymph nodes for cancer (usually with a sentinel lymph node biopsy, which checks the first few lymph nodes that drain the breast).

Surgery is commonly followed by radiation therapy to the remaining breast tissue (if BCS was done) or chest wall (for certain mastectomy patients) to kill any microscopic cancer cells and reduce the risk of the cancer coming back. For instance, after a lumpectomy, radiation to the breast is standard because it significantly lowers recurrence risk. Stage 0 (DCIS) is also often treated with lumpectomy plus radiation, or mastectomy in some cases, but chemotherapy is not needed for DCIS since it’s non-invasive.

In addition to local treatment, doctors consider systemic therapy (treatments that travel through the bloodstream) based on the tumor’s biology and risk factors. Many early-stage patients benefit from adjuvant therapy, which means extra treatment given after surgery to destroy any leftover cancer cells and help prevent recurrence. The choices can include:

• Hormone Therapy: If the cancer is ER or PR positive, patients will likely take hormonal therapy (such as tamoxifen or aromatase inhibitors) for several years after initial treatment. This medicine helps prevent hormone-driven cancer cells from growing. Hormone therapy greatly lowers the chance of hormone-positive cancers returning.
• Chemotherapy: If the cancer has a higher risk of coming back (for example, if it’s large, high-grade, or cancer was found in lymph nodes), chemotherapy may be recommended after surgery. Chemotherapy is a combination of drugs that kill rapidly dividing cells and can reduce the risk of recurrence for those higher-risk early cancers. In some cases, chemo might be given before surgery (neoadjuvant chemotherapy) to shrink a tumor and make surgery easier, particularly if the tumor is somewhat large for breast-conserving surgery.
• Targeted Therapy: If the tumor is HER2-positive, doctors will use HER2-targeted drugs (such as trastuzumab) in addition to chemo. These drugs specifically attack HER2-overexpressing cancer cells and have significantly improved outcomes for HER2-positive breast cancer. Targeted therapies are usually started with chemo (either before or after surgery) and continued for months to a year.

In summary, for early-stage breast cancer, the standard treatment often involves surgery and radiation, with the addition of hormone therapy, chemotherapy, and/or targeted therapy as appropriate to the cancer’s features. These treatments are very effective – most patients with Stage I or II breast cancer can be treated successfully and live long, healthy lives.

Locally Advanced Breast Cancer (Stage III)

Stage III breast cancer is sometimes called “locally advanced” disease. These tumors are larger (often over 5 cm) or have grown into nearby tissues (like chest muscle or skin), and/or the cancer has spread to multiple nearby lymph nodes. Although Stage III is still potentially curable, it requires a more aggressive treatment strategy that combines therapies.

A common approach for Stage III is to start with neoadjuvant therapy, which means treatment given before surgery. Typically, this is neoadjuvant chemotherapy aimed at shrinking the tumor and any involved lymph nodes. In HER2-positive Stage III cancers, targeted drugs such as trastuzumab (often along with pertuzumab) are added to the chemo regimen from the start. In some cases of Stage III that are triple-negative (ER/PR negative, HER2 negative), an immunotherapy drug (like pembrolizumab) may also be included with chemotherapy before surgery. By giving these treatments first, doctors hope to reduce the tumor’s size so that surgery can be more successful (for example, converting a required mastectomy into a possible lumpectomy). It also gives an early indication of how the cancer responds to therapy.

After neoadjuvant therapy, surgery is performed to remove the breast tumor and affected lymph nodes. In Stage III, surgery often means a mastectomy, because the tumors are usually large and may involve a significant portion of the breast. Some women may still have the option of breast-conserving surgery if the tumor has shrunk enough and is not involving the skin or chest wall. During surgery, an axillary lymph node dissection (removal of many lymph nodes in the armpit) is usually done for Stage III to thoroughly check how many nodes are involved, since cancers at this stage have higher lymph node spread.

Following surgery, radiation therapy to the chest/breast area and regional lymph nodes is almost always recommended in Stage III breast cancer. Radiation helps eradicate any remaining cancer cells in the breast area after a mastectomy or lumpectomy, and is important for controlling disease that had extensive lymph node involvement.

Stage III treatment doesn’t end with local therapy; it typically includes additional systemic therapy after surgery (or continued from before surgery). The exact regimen depends on the cancer’s characteristics and what was given neoadjuvantly. Many patients will receive more chemotherapy post-surgery, especially if any cancer was left after pre-surgical treatment. Patients with hormone receptor-positive tumors will be put on long-term hormone-blocking medications (endocrine therapy), similar to earlier stages. Those with HER2-positive cancer will continue HER2-targeted therapy for a total of 12 months of treatment (for example, finishing a year of trastuzumab). In situations where there was residual disease after neoadjuvant treatment, doctors may even switch to different medications (for instance, ado-trastuzumab emtansine for some HER2-positive cases, or adding other drugs like capecitabine or olaparib for certain high-risk cases) to reduce the chance of recurrence. In summary, Stage III breast cancer care is multi-modal: a combination of chemotherapy (and possibly other drug therapies), surgery, and radiation, in a sequence tailored to maximize the chances of eliminating the cancer.

Metastatic Breast Cancer (Stage IV)

Stage IV breast cancer means the cancer has spread beyond the breast and nearby lymph nodes to distant organs (most commonly the bones, lungs, liver, or brain). This advanced stage is also called metastatic breast cancer. While there have been major advances in treating Stage IV, it is generally not considered curable – the goal of treatment is to control the disease, relieve symptoms, and help patients live longer and as well as possible.

The cornerstone of therapy for metastatic breast cancer is systemic drug treatment, because the cancer cells may be in multiple areas of the body. The specific drugs depend on the characteristics of the cancer, but may include:

• Hormone Therapy: If the cancer is ER or PR positive (hormone receptor-positive), hormonal treatments (like aromatase inhibitors, tamoxifen, or ovarian suppression in premenopausal women) are usually the first-line approach. Often these are combined with targeted drugs (for example, CDK4/6 inhibitors such as palbociclib) to improve their effectiveness. Hormone therapies can control metastatic hormone-sensitive breast cancer for a long time in many cases.
• Chemotherapy: If the cancer is not hormone-sensitive, or if hormonal drugs stop working, chemotherapy is used. Chemotherapy attacks fast-growing cells and can shrink tumors throughout the body, which may relieve symptoms and extend survival. It’s often given in cycles and the regimen can be changed if one stops working.
• Targeted Therapy: Cancers that have specific genetic or protein markers are treated with targeted drugs. For HER2-positive metastatic breast cancer, combinations of anti-HER2 drugs (like trastuzumab, pertuzumab, or newer agents such as T-DM1 and tucatinib) with chemotherapy are standard, because they can significantly improve outcomes. Other targeted therapies might be used if the tumor has certain mutations (for example, a PARP inhibitor for BRCA-mutated cancers, or PI3K/AKT inhibitors for tumors with those pathway mutations).
• Immunotherapy: For some metastatic triple-negative breast cancers (which lack ER, PR, and HER2), immunotherapy drugs (like pembrolizumab or atezolizumab) combined with chemotherapy can help the immune system attack the cancer. Immunotherapy has shown benefit in a subset of patients with advanced disease.

Often, metastatic breast cancer treatment involves a combination of these systemic therapies, and over the course of a patient’s care, the treatment may be adjusted or switched based on what is controlling the cancer. Treatment is continuous in Stage IV (as long as it’s tolerated and effective) to keep the cancer in check.

In addition to drug therapies, local treatments like surgery or radiation are sometimes used in Stage IV, but their role is more limited. They are not typically done to cure the cancer, but rather to address specific problems. For example, surgery might be performed to remove a breast tumor that is causing pain or an open wound in the breast, or to stabilize a bone that has a risky lesion. Radiation therapy can be very helpful to relieve pain (such as from bone metastases) or to treat a troublesome spot like a single brain or spine metastasis causing symptoms. These treatments can greatly improve quality of life by reducing pain or preventing complications in areas where the cancer has spread. However, the primary focus for Stage IV is systemic treatment, since we need to treat cancer throughout the body.

It’s important to note that every metastatic breast cancer patient’s situation is unique. While doctors aim to shrink tumors and control the disease (often achieving long periods of remission), Stage IV breast cancer is considered chronic and currently cannot be cured. The emphasis is on selecting therapies that can extend life and maintain a good quality of life, with close monitoring and supportive care for symptoms. Many patients with Stage IV breast cancer live for years with ongoing treatment, and new therapies continue to improve outcomes.

Looking for breast cancer support resources near you?
Use WeTrials’ Breast Cancer to explore patient-friendly trial options, support resources, and expert insights.

References:

1. Canadian Cancer Society: Diagnostic Steps Read More
2. American Cancer Society: Treatment by Stage Read More
3. American Cancer Society: Mammograms Read More
4. American Cancer Society: Breast MRI Read More